building extraordinary life science companies on both sides of the atlantic
AdoRx Therapeutics
Edinburgh, United Kingdom
AdoRx is developing new modulators of the adenosine pathway for the treatment of cancer.
Apellis Pharmaceuticals
Louisville, Kentucky
Apellis is a NASDAQ listed company developing therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within haematology, ophthalmology, and nephrology.
Caldan Therapeutics
Edinburgh, United Kingdom
Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for metabolic diseases. The lead programme aims to develop a selective FFA4 (GPR120) agonist for Non-Alcoholic Steatohepatitis (NASH).
Clyde Biosciences
Glasgow, United Kingdom
Clyde Biosciences, a spin-out company from the University of Glasgow, has developed a pioneering technology (CellOPTIQ) to rapidly evaluate cardiotoxicity risk in pharmaceuticals.
Confluence Life Sciences
St. Louis, Missouri
Confluence Life Sciences, Inc., a technology-based company focusing on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases, was acquired by Aclaris Therapeutics (ACRS).
Acquired August 2017
Curve Therapeutics
London, United Kingdom
Curve a spin-out from the University of Southampton, Curve is deploying its MicrocycleTM platform to build a pipeline of first-in-class therapeutics targeting protein-protein interactions. Curve’s goal is to transform the discovery of new therapeutics through functional screening against intractable targets in their native cellular environment.
DUNAD Therapeutics
Cambridge, United Kingdom
Dunad is focusing on the development of next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology.
Edinburgh Molecular Imaging
Edinburgh, United Kingdom
EM Imaging, a spin-out company from the University of Edinburgh, is a clinical phase biotechnology company with a highly novel C-Met molecular targeting technology platform. It is developing a radiotherapeutic agent for treatment in cancer, alongside its fluorescent optical imaging agent.
Enterprise Therapeutics
Brighton, United Kingdom
Enterprise Therapeutics is a clinical stage company dedicated to the research and development of novel therapies for the treatment of respiratory diseases through the modulation of ion channels.
Epsilogen
London, United Kingdom
Epsilogen (formerly IGEM Therapeutics) is a clinical stage company, spun-out from King’s College London, is developing IgE-based antibody therapeutics for the treatment of cancer.
Harness
Cambridge, United Kingdom
Harness Therapeutics (formerly Transine Therapeutics) is focused on RNA-targeted upregulation of new targets to transform treatment of neurodegenerative diseases.
Harpoon Medical, Inc.
Baltimore, Maryland
Harpoon Medical, Inc. a medical device, spun-out from the University of Maryland, Baltimore (UMB) commercializing a minimally invasive, image-guided surgical tool for beating heart mitral valve repair, as acquired by Edwards Lifesciences Corporation (EW).
Acquired December 2017
Kodikaz Therapeutic Solutions
New York, New York
Kodikaz Therapeutic Solutions, a preclinical stage spin out from Emory University, is developing a novel nucleic acid based targeted delivery platform for cancer therapeutics.
Kynos Therapeutics
Edinburgh, United Kingdom
Kynos Therapeutics, a spin-out from the University of Edinburgh, is an immunemetabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3monooxygenase (KMO) biology.
Lario Therapeutics
Edinburgh, United Kingdom
Lario Therapeutics is a preclinical-stage drug discovery company. Incubated and co-founded by Epidarex-Exeed and Axxam SpA, Lario is developing first-in-class precision medicines for epileptic and neurological disorders.
Leucid Bio
London, United Kingdom
Leucid Bio, a spin out company from King’s College London is focused on the development of new treatments for cancer. The company is developing a pioneering technology utilising engineered T cells.
Libra Therapeutics
San Diego, California
Libra Therapeutics is a US biotech focused on developing novel therapeutics for neurodegenerative diseases by normalizing intracellular trafficking and autophagy in neuronal cells.
Lunac Therapeutics
Leeds, United Kingdom
LUNAC Therapeutics, a spin-out company from the University of Leeds, is developing next generation oral anticoagulants for the treatment and prevention of life-threatening thrombotic events.
Macomics
Edinburgh, United Kingdom
Macomics, an early-stage immuno-oncology company, spun-out from the University of Edinburgh, its developing next-generation therapies to modulate macrophages, increasing the body’s immune defence against tumours.
Mironid
Glasgow, United Kingdom
Mironid is developing proprietary drug candidates that modulate the activity of key phosphodiesterase 4 (PDE4) enzymes in chronic inflammatory and degenerative kidney diseases.
NodThera
Cambridge, United Kingdom
NodThera is a clinical stage company developing NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
Nyra Medical
Atlanta, Georgia
Nyra Medical, a spinout from Emory University, is developing a novel transcatheter mitral valve repair technology to treat functional mitral regurgitation.
RapidPulse, Inc.
Miami, Florida
RapidPulse, a spin out from medical device incubator and engineering firm Syntheon, is developing a novel RapidPulse aspiration system to treat ischemic stroke.
Ryme Medical
San Francisco, California
Ryme Medical is a device company developing a novel catheter-based treatment for COPD.
Slate Bio, Inc.
Charlottesville, Virginia
Slate Bio, a spin out from the University of Virginia, is developing next generation IL-2 therapies that restore the body’s natural immunological response in various diseases.
SIRAKOSS
Aberdeen, United Kingdom
SIRAKOSS, a spin-out company from the University of Aberdeen, is developing nano-synthetic bone graft substitutes to facilitate bone repair utilising advanced nanostructures to catalyse faster bone regeneration.
Acquired November 2020
Theolytics
Oxford, United Kingdom
Theolytics, is a UK biotech focused on creating a step-change in the oncolytic viral therapy field, by using its patient-centric phenotypic screening platform.
Topas Therapeutics
Hamburg, Germany
Topas is a clinical stage therapeutics company using ground-breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen-specific immune tolerance in the liver.